$DFTX

Definium Therapeutics (DFTX) reported positive Phase 3 results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. Shares have surged 12.88% in 7 days and 121.27% in 90 days, with a 1-year return of 391.80%. Analysts estimate revenue of $320.2M by July 2029 and a 1.7% profit margin, suggesting a 22.3% undervaluation at $46.18 vs. a $59.47 fair value.

Simply Wall St reports Definium Therapeutics (DFTX) shares fell about 5.6% after the company said its Phase 3 Voyage trial of DT120 ODT for generalized anxiety disorder met the primary and key secondary endpoints, with statistically significant HAM-A score reductions versus placebo and generally mild to moderate transient side effects. The article cites Q2 2026 net loss of $159.0M and $236.1M for 1H 2026.

Definium Therapeutics, Inc. (DFTX) said Commodore Capital and related filers reported a Schedule 13G showing beneficial ownership of 2,410,000 common shares, including 410,000 shares issuable from a pre-funded warrant, as of June 30, 2026. The stake equals 1.8% of 134,365,950 shares outstanding, with shared voting and dispositive power.

Definium Therapeutics (DFTX) reported positive topline Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder, saying the study met its primary HAM-A endpoint and key secondary measures with generally well-tolerated safety and no new signals. The stock closed at $43.90. Analysts cite an average target of $67 and fair value of $59.47, with 2029 consensus revenue of $320.2M.

Definium Therapeutics (DFTX) shares rose about 9% after its Phase 3 Voyage trial reported that a single 100 µg dose of DT120 reduced anxiety symptoms in adults with generalized anxiety disorder versus placebo. The company said the HAM-A improvement was 11.6 points vs 6.2 at 12 weeks, with 43% vs 16% achieving at least 50% symptom reduction. Panorama Phase 3 results are expected in September.

Simply Wall St reports Definium Therapeutics (DFTX) drew renewed attention after positive topline results from its Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. The stock last traded at $43.90, with an average analyst target of $67 and internal fair value around $59.47. DFTX has no revenue; analysts forecast $320.2M by July 2029.

Definium Therapeutics (NASDAQ:DFTX) reported DT120 met Phase III goals in a GAD study. At week 1, HAM-A improved 11.9 points from baseline, 7.7 placebo-adjusted, with p<0.0001 at all time points. At week 12, remission was 14% vs 4% placebo; response 43% vs 16%. DT120 was generally well tolerated; no serious AEs or deaths in DT120.

Definium Therapeutics (Nasdaq: DFTX) reported positive topline Phase 3 Voyage results for DT120 (lysergide) ODT 100 µg in adults with generalized anxiety disorder. The study met primary and key secondary endpoints, with HAM-A Week 12 placebo-adjusted change of 5.4 points (p<0.0001). DT120 was generally well tolerated; no new safety signals. Webcast scheduled for 8:00 am EDT.

Definium Therapeutics (NASDAQ:DFTX) shares rose about 20% premarket after positive topline Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder. The study met its primary endpoint and key secondary endpoints, with placebo-adjusted HAM-A reduction of 5.4 points at Week 12 (p<0.0001). Safety was generally mild to moderate with no new signals.

Definium Therapeutics (NASDAQ:DFTX) reported Q2 results and discussed Phase II GAD data for DT120, saying efficacy was seen by week one and remained significant through week 12, with improvements on secondary endpoints and favorable tolerability. It said VOYAGE and PANORAMA were re-estimated to exceed 99% power. Net loss was $159M, including $86.2M non-cash warrant fair-value expense. The company raised about $758M net in June and had about $1.1B cash to fund operations into 2030.